Company: DVAX
Filing Date: 2025-06-09
Form Type: DEFA14A
Source: 0001193125-25-137437
Chunk: 2

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-06-09
Form: DEFA14A
Chunk 2
---
tested”and “may raise legitimate questions about Mr. Erkman’s ability to balance Deep Track’s position with the broader interests of all shareholders.” 2

Here’s why we encourage you to vote for ALL four of Dynavax’s nominees:

| • |     | The strategy Dynavax has in place, and is successfully executing against, is working. We positioned HEPLISAV-B® to be the market-leading hepatitis B vaccine, and are consistently delivering record financial results, including most recently a few weeks ago 
 when we reported Q1 2025 results, and have delivered 203% total return to stockholders over the last five years3. We are far outperforming vaccine peers, which have returned 9%, and the S&P                                                                   
 Biotechnology Select Industry Index, which has declined 17%. This is the result of consistent operational execution, skilled business development which generated over $950 million in revenue between 2020 and 2022, and a disciplined capital                 
 allocation plan that, as of May 5, 2025, included execution of over 85% of the $200 million share repurchase program authorized in November 2024.                                                                                                               |

| • |     | The directors Dynavax needs at this time are already on the Board. The Board has been thoughtfully                                                                                                                                              
 reshaped in recent years with new, independent directors – following the Annual Meeting, the Board will be comprised of nine directors, with six of eight independent directors having been appointed since 2020 – who bring highly specialized 
 skillsets that are directly aligned to our long-term strategic plan. Our directors, including those up for re-election, are renowned experts in their fields within biotech and vaccines across operations,                                     
 finance/capital markets, business development M&A, commercialization, R&D, public health and more. Replacing any Dynavax directors with Deep Track’s underqualified nominees would disrupt the momentum of our clearly successful long-term     
 strategy and put stockholder value at risk.                                                                                                                                                                                                     |

With our 2025 Annual Meeting fast approaching on June 11, it is extremely important that you vote as soon as possible, no matter how many shares you own. We urge you to vote “FOR” all four of Dynavax’s director nominees – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun – on the GOLD proxy card today. Dynavax stockholders who need assistance in voting their shares may call the Company’s proxy solicitor, MacKenzie Partners, at 1-800